scPharmaceuticals Inc. (2SX.F)

4.2400 +0.0400 (+0.95%) At close: 08:32AM CEST

scPharmaceuticals Inc.

25 Mall Road
Suite 203
Burlington, MA 01803
United States
617 517 0730
https://www.scpharmaceuticals.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 135

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John H. Tucker	President, CEO, Principal Executive Officer & Director	921.34k	N/A	1963
Ms. Rachael Nokes	CFO & Principal Accounting Officer	538.6k	N/A	1976
Mr. Michael D. Hassman	Senior Vice President of Technical Operations	N/A	N/A	N/A
Katherine Taudvin	Vice President of Corporate Affairs & Human Resources	N/A	N/A	N/A
Dr. John Mohr Pharm.D.	Senior Vice President of Clinical Development & Medical Affairs	N/A	N/A	N/A
Steve Parsons	Senior Vice President of Commercial	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Corporate governance

scPharmaceuticals Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.